227 related articles for article (PubMed ID: 18300641)
1. [Metastatic breast cancer--new methods of treatment].
Rack B; Heinemann V; Schindlbeck C; Walther J; Salat C; Sommer H
MMW Fortschr Med; 2008 Jan; 150(1-2):34-6. PubMed ID: 18300641
[No Abstract] [Full Text] [Related]
2. Osteonecrosis of the jaw and bevacizumab therapy.
Van Poznak C
Breast Cancer Res Treat; 2010 Jul; 122(1):189-91. PubMed ID: 20464477
[No Abstract] [Full Text] [Related]
3. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
4. [New treatment approaches in breast cancer].
Spirig C; Thürlimann B; Huober J
Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
[TBL] [Abstract][Full Text] [Related]
5. Ten years of HER2-directed therapy: still questions after all these years.
Krop IE; Winer EP
Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
[No Abstract] [Full Text] [Related]
6. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Pérol M
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
[No Abstract] [Full Text] [Related]
7. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
8. Targeting alternative pathways in HER2-positive breast cancer.
Rastogi P
Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
[No Abstract] [Full Text] [Related]
9. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Pikó B
Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
[TBL] [Abstract][Full Text] [Related]
10. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for breast cancer: questions answered, questions remaining.
Layman R; Olson K; Van Poznak C
Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
[TBL] [Abstract][Full Text] [Related]
12. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Nielsen DL; Andersson M
Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Spector N
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of lapatinib in HER2-positive breast cancer.
Ulhoa-Cintra A; Greenberg L; Geyer CE
Curr Oncol Rep; 2008 Jan; 10(1):10-7. PubMed ID: 18366956
[TBL] [Abstract][Full Text] [Related]
18. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
19. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
20. Lapatinib: a competitor or companion to trastuzumab?
Collins D; Hill AD; Young L
Cancer Treat Rev; 2009 Nov; 35(7):574-81. PubMed ID: 19748186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
